Company Filing History:
Years Active: 2012-2022
Title: Rachel Cohen-Kupiec: Innovator in Cellular and Antibody Research
Introduction
Rachel Cohen-Kupiec is a prominent inventor based in Tel Aviv, Israel. She has made significant contributions to the fields of cellular biology and antibody research. With a total of 3 patents, her work focuses on innovative methods that have the potential to impact medical science.
Latest Patents
Cohen-Kupiec's latest patents include groundbreaking methods for modifying the growth rate of cells. These genetically modified cells feature at least one codon substituted to a synonymous codon, which alters their replicative fitness compared to unmodified cells. Notably, a slower translating synonymous codon enhances replicative fitness, while a faster translating codon diminishes it. Additionally, she has developed a vaccine composition that utilizes these modified cells, along with methods for further modifying the replicative fitness of a cell. Another significant patent involves single chain antibodies against β-amyloid peptide. These anti-AβP scFvs and single domain antibodies can prevent the fibrilization of Aβp 1-40 and disaggregate Aβp 1-40 fibrils generated in vitro. Furthermore, these antibodies have shown efficacy in staining amyloid neuritic plaques on slices from transgenic mice, indicating their potential use in inhibiting or treating Alzheimer's disease.
Career Highlights
Cohen-Kupiec is affiliated with Tel Aviv University, where she conducts her research and develops her innovative ideas. Her work has garnered attention for its potential applications in treating neurodegenerative diseases and enhancing cellular functions.
Collaborations
Some of her notable coworkers include Beka Solomon and Tamir Tuller, who contribute to her research endeavors and collaborative projects.
Conclusion
Rachel Cohen-Kupiec stands out as an influential inventor whose work in cellular and antibody research holds promise for future medical advancements. Her innovative patents reflect her commitment to addressing critical health challenges.